

細胞及基因療法研發
02-26558766
17人
新北市汐止區新台五路一段95號23樓(C棟)
Company at a glance At GenomeFrontier, our mission is to develop innovative gene therapies that are therapeutically effective and affordable, and with easy worldwide access. CAR-T therapy has been touted as a paradigm changing gene therapy for treatment of liquid cancers. However, it is not effective against solid tumors. Using CAR-T as the first focus to demonstrate the power of our virus-free Quantum Engine™ for cell engineering, we have established Quantum CART™ (qCART™) system which is tailored specifically for engineering and production of efficacious therapies to overcome CAR-T obstacles, including those for treating solid cancers. Seeking for talents Our team members share a burning desire to innovate for humanity and strive towards creating a disease-free world. We cultivate an infinite mindset by promoting character-based and principle-driven way of life. We value three key qualities: passion, discipline, and principle-driven thinking. We believe that persons embodying these qualities will lead an extraordinary life, which fosters a win-win-win situation for our team member, the company and humanity as a whole. We therefore seek talents who also possess an infinite mindset and are passionate about striving for an extraordinary life to join our team at GenomeFrontier. We believe that by combining this mindset with discipline, timeless principles, and the right state of mind, we can achieve extraordinary results and greatly impact the world for everyone. Currently, we are looking for talents in the following areas: 1. Research Scientist - Immunologist • PhD in immunology, molecular biology, cell biology, or related life sciences. • Knowledge in immunology and extensive experience in antibody biology and immune oncology studies carried out in mice. • Expertise in independent establishment and analyses of immune cell culture systems. 2. Research Scientist – Stem Cell Biologist • PhD in cell biology, molecular biology, or related life sciences. • Knowledge and extensive experience in the areas of induced pluripotent stem (iPS) cell and/or embryonic stem (ES) cell differentiation, especially in application of these knowledge in immunology.
CAR-T細胞療法,是將取自病患之T細胞加以基因體改造、大量培養、再輸回病患體內,使之主動辨識並殲滅癌細胞之新型療法。此新療法”對症下藥”,打破傳統以被動式強化病患自身免疫系統之舊思維,主動為患者量身打造更具專一性、殺傷力、存活力之抗癌尖兵-殺手T細胞,因而療效驚人,對末期血癌病患可達90%之治癒率。諾華的Kymriah的CAR-T療法成為美國FDA首度核准上市的基因治療藥物,使新藥研發正式邁入基因改造細胞療法的新紀元。而CAR-T免疫療法也必然成為未來抗癌新藥研發之主流。 目前所有CAR-T療法都以病毒為基因體改造的工具,但其安全性堪慮,製造成本高昂且基因承載力小。上述本質上的種種缺陷使之無法在實體腫瘤上有重大突破。再者,目前CAR-T療法普遍存在的問題為: 如何承載更大基因片段進入細胞內,以及如何在大量培養CAR-T細胞的同時亦能保有其最佳效力。針對現今CAR-T所面臨的重大挑戰,本公司非病毒的Quantum CART™(qCART™)系統,透過旗下的四大平台:GTailor、Quantum pBac、Quantum Nufect和iCellar,所研發出下一代CAR-T製程,已具備解決目前CAR-T療法的瓶頸的能力。 本公司以CAR-T療法拓展治療各式疾病之無限潛能的同時,亦肩負起為此療法之安全把關的時代使命。除創辦者經營團隊外,亦有大型生技創投基金及國內外生醫界專家為公司股東,股東陣容堅強。近期內將與大型券商合作,起動進入資本市場程序。值此需要各路菁英來茁壯我們之際,誠摯邀請對研發深具熱忱之青年志士加入我們的團隊。